VAV1-degrader
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Actionable Insights Powered by AI
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration